摘要
应用我室制备卵巢上皮癌单抗 COC 183 B_2经^(131)Ⅱ标记后进行45例 RⅡ,30例为术前诊为卵巢癌或可疑者,15例为卵巢上皮癌手术化疗后追踪患者,RII结果与手术病理对照,敏感性达87.5％,特异性达93.1％;如按单抗与癌组织免疫组化染色衡量,则分别为100％及96.7％。追踪治疗后患者,先作第一次手术癌组织与COC183 B_2、PAP染色,RII均与此结果符合。合并有腹水患者先取腹水,用多种单抗进行免疫细胞化学染色,选其阳性反应强的单抗作RII,可提高显像率及准确性。本文提示选择与腹水中癌细胞免疫细胞化学染色,及与癌组织免疫组化染色的单抗来作RII是成功的关键。为临床分期、鉴别诊断及追踪检测等,提供有力的手段。
Results of 45 cases in radioimmunoimaging (RII) by ^(131)I--COC 183 B 2, monoclonal antibody(MAb) against ovarian carcinoma were studied. 30 of them were diagnosed as ovarian carcinoma orcases in doubt while 15 follow-up cases were proved ovarian carcinoma after initial surgery andchemotherapy before the second operation. The sensitivity was 87.5％ and specificity 93.1％. Ifmeasured by immuno?tochemical staining (PAP method) they would be 100％ and 96.7％ respecti-vely. The key point for RII was the MAb that had been used. For follow-up cases PAP stainingwith the tumor tissue taken from the initial surgery is very important. In cases complicated withascites the MAb which stained positively with cancer cells from the ascites was chosen for RII. RIIis a good method for clinical staging, tumor localization before surgery as well as follow-upexaminations.
出处
《北京医科大学学报》
CSCD
1992年第2期89-92,T009,共5页
Journal of Peking University(Health Sciences)
关键词
放免显象
卵巢肿瘤
单克隆抗体
Monoclonal antibody
Radioimmunoimaging
Immunocytochemical staining
Immunohistochemical staining
